Toward a Dimensional Approach of Hypersomnolence: Psychometric Validation of the French Version of the Hypersomnia Severity Index in a National Quota-Based Sample of the General Population
Abstract
The Hypersomnia Severity Index (HSI) is a self-report instrument assessing hypersomnolence using a dimensional approach based on two factors: symptoms and distress/impairment. This study aimed to translate, adapt, and validate the French version of the HSI in a large quota-based sample of the French general population, and to propose an original dimensional visualization of hypersomnolence profiles. Following a forward–backward translation procedure, the French HSI was administered to 1,000 adults aged 18–65 from the general French population. Internal consistency and structural validity were assessed using confirmatory factor analysis (CFA) and exploratory factor analysis (EFA) when necessary. External validity was examined through correlations with validated self-report measures of hypersomnolence and sleep-related parameters. An original polar chart visualization was developed to represent item-level HSI profiles. The French HSI demonstrated good internal consistency (Cronbach’s α = 0.82). CFA did not confirm an adequate fit for the original two-factor model. EFA confirmed the distress/impairment factor but split the symptoms factor into two subfactors, labeled “sleepiness symptoms” and “alertness symptoms.” HSI scores were significantly correlated with established hypersomnolence and sleep-related measures, supporting convergent validity. Polar chart visualizations revealed distinct symptom patterns across subgroups, supporting the identification of dimensional hypersomnolence symptom profiles. The French version of the HSI is a reliable and clinically meaningful instrument for the dimensional assessment of hypersomnolence. Its cross-cultural validation supports its use in research and clinical practice. The HSI provides a multidimensional and easily administered measure, with potential utility for symptom profiling and monitoring hypersomnolence. Future studies should examine its longitudinal sensitivity and prognostic value.
Related
- Development and psychometric validation of Mpox knowledge and preventive behavior measures in the Turkish population
- Psychometric Validation of the Ageism Scale for the Portuguese Context
- AI acceptance and behavioral intention in pharmacy education: Scale development, psychometric validation, and correlates
- Psychometric validation of the perceived digital well-being scale and digital well-being questionnaire among adolescents receiving psychiatric care
- Cross-cultural adaptation and psychometric validation of the ISBAR structured handover observation tool for ICU-to-ward patient transfer in China
BibTeX
@article{massiah2026toward,
title = {{Toward a Dimensional Approach of Hypersomnolence: Psychometric Validation of the French Version of the Hypersomnia Severity Index in a National Quota-Based Sample of the General Population}},
author = {Benjamin Massiah and Julien Coelho and Marc Rey and Marie Françoise Vecchierini and Sarah Hartley and Pierre-Alexis Geoffroy and Clélia Quiles and Laure Peter-Derex and Aileen Mcgonigal and Isabelle Lambert and Régis Lopez and Vincent P. Martin and Pierre Philip and Isabelle Poirot and Claude Gronfier and Katherine Kaplan and Jean-Arthur Micoulaud-Franchi},
journal = {Sleep Epidemiology},
year = {2026},
month = jun,
doi = {10.1016/j.sleepe.2026.100146},
url = {https://hal.science/hal-05667674v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Toward a Dimensional Approach of Hypersomnolence: Psychometric Validation of the French Version of the Hypersomnia Severity Index in a National Quota-Based Sample of the General Population
AU - Benjamin Massiah
AU - Julien Coelho
AU - Marc Rey
AU - Marie Françoise Vecchierini
AU - Sarah Hartley
AU - Pierre-Alexis Geoffroy
AU - Clélia Quiles
AU - Laure Peter-Derex
AU - Aileen Mcgonigal
AU - Isabelle Lambert
AU - Régis Lopez
AU - Vincent P. Martin
AU - Pierre Philip
AU - Isabelle Poirot
AU - Claude Gronfier
AU - Katherine Kaplan
AU - Jean-Arthur Micoulaud-Franchi
PY - 2026
DA - 2026/06/23
JO - Sleep Epidemiology
DO - 10.1016/j.sleepe.2026.100146
UR - https://hal.science/hal-05667674v1
AB - The Hypersomnia Severity Index (HSI) is a self-report instrument assessing hypersomnolence using a dimensional approach based on two factors: symptoms and distress/impairment. This study aimed to translate, adapt, and validate the French version of the HSI in a large quota-based sample of the French general population, and to propose an original dimensional visualization of hypersomnolence profiles. Following a forward–backward translation procedure, the French HSI was administered to 1,000 adults aged 18–65 from the general French population. Internal consistency and structural validity were assessed using confirmatory factor analysis (CFA) and exploratory factor analysis (EFA) when necessary. External validity was examined through correlations with validated self-report measures of hypersomnolence and sleep-related parameters. An original polar chart visualization was developed to represent item-level HSI profiles. The French HSI demonstrated good internal consistency (Cronbach’s α = 0.82). CFA did not confirm an adequate fit for the original two-factor model. EFA confirmed the distress/impairment factor but split the symptoms factor into two subfactors, labeled “sleepiness symptoms” and “alertness symptoms.” HSI scores were significantly correlated with established hypersomnolence and sleep-related measures, supporting convergent validity. Polar chart visualizations revealed distinct symptom patterns across subgroups, supporting the identification of dimensional hypersomnolence symptom profiles. The French version of the HSI is a reliable and clinically meaningful instrument for the dimensional assessment of hypersomnolence. Its cross-cultural validation supports its use in research and clinical practice. The HSI provides a multidimensional and easily administered measure, with potential utility for symptom profiling and monitoring hypersomnolence. Future studies should examine its longitudinal sensitivity and prognostic value.
SN - 2667-3436
ER -